101 related articles for article (PubMed ID: 20930673)
1. Resecting an unresectable tumor?
Hatooka S
Ann Thorac Cardiovasc Surg; 2010 Jun; 16(3):147-9. PubMed ID: 20930673
[No Abstract] [Full Text] [Related]
2. Salvage esophagectomy after definitive chemotherapy and radiotherapy for advanced esophageal cancer.
Nakamura T; Hayashi K; Ota M; Eguchi R; Ide H; Takasaki K; Mitsuhashi N
Am J Surg; 2004 Sep; 188(3):261-6. PubMed ID: 15450831
[TBL] [Abstract][Full Text] [Related]
3. Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer.
Meredith KL; Weber JM; Turaga KK; Siegel EM; McLoughlin J; Hoffe S; Marcovalerio M; Shah N; Kelley S; Karl R
Ann Surg Oncol; 2010 Apr; 17(4):1159-67. PubMed ID: 20140529
[TBL] [Abstract][Full Text] [Related]
4. Esophageal cancer.
Block M
J S C Med Assoc; 2003 Apr; 99(4):98-103. PubMed ID: 12762157
[No Abstract] [Full Text] [Related]
5. Neoadjuvant strategies for the treatment of locally advanced esophageal cancer.
Hyngstrom JR; Posner MC
J Surg Oncol; 2010 Mar; 101(4):299-304. PubMed ID: 20187065
[TBL] [Abstract][Full Text] [Related]
6. Treatment of oesophageal squamous cell carcinoma in a patient with Fanconi anaemia.
Tipples K; Raouf S
Clin Oncol (R Coll Radiol); 2008 Jun; 20(5):383-4. PubMed ID: 18387792
[No Abstract] [Full Text] [Related]
7. Influence of neoadjuvant chemoradiation on the number and size of analyzed lymph nodes in esophageal cancer.
Bollschweiler E; Besch S; Drebber U; Schröder W; Mönig SP; Vallböhmer D; Baldus SE; Metzger R; Hölscher AH
Ann Surg Oncol; 2010 Dec; 17(12):3187-94. PubMed ID: 20585867
[TBL] [Abstract][Full Text] [Related]
8. A multicenter study of survival after neoadjuvant radiotherapy/chemotherapy and esophagectomy for ypT0N0M0R0 esophageal cancer.
Vallböhmer D; Hölscher AH; DeMeester S; DeMeester T; Salo J; Peters J; Lerut T; Swisher SG; Schröder W; Bollschweiler E; Hofstetter W
Ann Surg; 2010 Nov; 252(5):744-9. PubMed ID: 21037429
[TBL] [Abstract][Full Text] [Related]
9. Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response.
Barbour AP; Jones M; Gonen M; Gotley DC; Thomas J; Thomson DB; Burmeister B; Smithers BM
Ann Surg Oncol; 2008 Oct; 15(10):2894-902. PubMed ID: 18663531
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of endoscopic biopsy findings after induction chemoradiotherapy with and without surgery for esophageal cancer.
Miyata H; Yamasaki M; Takiguchi S; Nakajima K; Fujiwara Y; Konishi K; Morii E; Mori M; Doki Y
Ann Surg; 2011 Feb; 253(2):279-84. PubMed ID: 21169807
[TBL] [Abstract][Full Text] [Related]
11. Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.
Castoro C; Scarpa M; Cagol M; Ruol A; Cavallin F; Alfieri R; Zanchettin G; Rugge M; Ancona E
Ann Surg Oncol; 2011 Dec; 18(13):3743-54. PubMed ID: 21556952
[TBL] [Abstract][Full Text] [Related]
12. High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer.
Xi H; Baldus SE; Warnecke-Eberz U; Brabender J; Neiss S; Metzger R; Ling FC; Dienes HP; Bollschweiler E; Moenig S; Mueller RP; Hoelscher AH; Schneider PM
Clin Cancer Res; 2005 Dec; 11(23):8341-7. PubMed ID: 16322294
[TBL] [Abstract][Full Text] [Related]
13. Current status of multimodality therapy for esophageal carcinoma.
Tak VM; Naunheim KS
J Surg Res; 2004 Mar; 117(1):22-9. PubMed ID: 15013710
[No Abstract] [Full Text] [Related]
14. Neoadjuvant chemoradiation versus chemotherapy for patients undergoing esophagectomy for esophageal cancer.
Luu TD; Gaur P; Force SD; Staley CA; Mansour KA; Miller JI; Miller DL
Ann Thorac Surg; 2008 Apr; 85(4):1217-23; discussion 1223-4. PubMed ID: 18355499
[TBL] [Abstract][Full Text] [Related]
15. The value of post-neoadjuvant therapy PET-CT in the detection of interval metastases in esophageal carcinoma.
Blom RL; Schreurs WM; Belgers HJ; Oostenbrug LE; Vliegen RF; Sosef MN
Eur J Surg Oncol; 2011 Sep; 37(9):774-8. PubMed ID: 21726976
[TBL] [Abstract][Full Text] [Related]
16. [Perioperative multi-modality treatment strategies in esophageal cancer].
Porschen R
Z Gastroenterol; 1993 Nov; 31(11):680-5. PubMed ID: 8291282
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant chemotherapy in esophageal cancer.
Picone V; D'Auria G; Ferraldeschi R; Grande R; Passeri V; Ranuncoli A; Di Bartolomeo C; Evangelista ML; Cortesi E
Rays; 2006; 31(1):31-5. PubMed ID: 16999373
[TBL] [Abstract][Full Text] [Related]
18. Death-associated protein kinase (DAPK) promoter methylation and response to neoadjuvant radiochemotherapy in esophageal cancer.
Brabender J; Arbab D; Huan X; Vallböhmer D; Grimminger P; Ling F; Neiss S; Bollschweiler E; Schneider PM; Hölscher AH; Metzger R
Ann Surg Oncol; 2009 May; 16(5):1378-83. PubMed ID: 19224282
[TBL] [Abstract][Full Text] [Related]
19. [Cancers of the esophagus. Combined modality therapy by radiotherapy, chemotherapy with or without surgery].
Calais G; Bedenne L
Bull Cancer Radiother; 1995; 82(2):137-46. PubMed ID: 7546884
[No Abstract] [Full Text] [Related]
20. Histopathologic examination and reporting of esophageal carcinomas following preoperative neoadjuvant therapy: practical guidelines and current issues.
Chang F; Deere H; Mahadeva U; George S
Am J Clin Pathol; 2008 Feb; 129(2):252-62. PubMed ID: 18208806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
